Breitz H - Search Results

1

Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.

Forero-Torres A, Shen S, Breitz H, Sims RB, Axworthy DB, Khazaeli MB, Chen KH, Percent I, Besh S, LoBuglio AF, Meredith RF. Forero-Torres A, et al. Among authors: breitz h. Cancer Biother Radiopharm. 2005 Aug;20(4):379-90. doi: 10.1089/cbr.2005.20.379. Cancer Biother Radiopharm. 2005. PMID: 16114986 Clinical Trial.

2

Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.

Shen S, Forero A, LoBuglio AF, Breitz H, Khazaeli MB, Fisher DR, Wang W, Meredith RF. Shen S, et al. Among authors: breitz h. J Nucl Med. 2005 Apr;46(4):642-51. J Nucl Med. 2005. PMID: 15809487 Free article. Clinical Trial.

3

Testicular uptake and radiation dose in patients receiving Zevalin and Pretarget CC49Fusion protein.

Shen S, Meredith R, Duan J, Forero A, Breitz H, Khazaeli MB, Brezovich I, LoBuglio A. Shen S, et al. Among authors: breitz h. Cancer Biother Radiopharm. 2005 Feb;20(1):110-8. doi: 10.1089/cbr.2005.20.110. Cancer Biother Radiopharm. 2005. PMID: 15778590

4

Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma.

Forero A, Weiden PL, Vose JM, Knox SJ, LoBuglio AF, Hankins J, Goris ML, Picozzi VJ, Axworthy DB, Breitz HB, Sims RB, Ghalie RG, Shen S, Meredith RF. Forero A, et al. Blood. 2004 Jul 1;104(1):227-36. doi: 10.1182/blood-2003-09-3284. Epub 2004 Mar 2. Blood. 2004. PMID: 14996706 Free article. Clinical Trial.

5

Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.

Weiden PL, Breitz HB, Press O, Appelbaum JW, Bryan JK, Gaffigan S, Stone D, Axworthy D, Fisher D, Reno J. Weiden PL, et al. Among authors: breitz hb. Cancer Biother Radiopharm. 2000 Feb;15(1):15-29. doi: 10.1089/cbr.2000.15.15. Cancer Biother Radiopharm. 2000. PMID: 10740649 Clinical Trial.

6

Dosimetry of solid tumors.

Meredith RF, Johnson TK, Plott G, Macey DJ, Vessella RL, Wilson LA, Breitz HB, Williams LE. Meredith RF, et al. Among authors: breitz hb. Med Phys. 1993 Mar-Apr;20(2 Pt 2):583-92. doi: 10.1118/1.597053. Med Phys. 1993. PMID: 8492767 Review.

7

Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin.

Breitz HB, Weiden PL, Beaumier PL, Axworthy DB, Seiler C, Su FM, Graves S, Bryan K, Reno JM. Breitz HB, et al. J Nucl Med. 2000 Jan;41(1):131-40. J Nucl Med. 2000. PMID: 10647616 Free article.

8

Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.

Knox SJ, Goris ML, Tempero M, Weiden PL, Gentner L, Breitz H, Adams GP, Axworthy D, Gaffigan S, Bryan K, Fisher DR, Colcher D, Horak ID, Weiner LM. Knox SJ, et al. Among authors: breitz h. Clin Cancer Res. 2000 Feb;6(2):406-14. Clin Cancer Res. 2000. PMID: 10690517 Clinical Trial.

9

Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.

Wessels BW, Bolch WE, Bouchet LG, Breitz HB, Denardo GL, Meredith RF, Stabin MG, Sgouros G; American Association of Physicists in Medicine. Wessels BW, et al. Among authors: breitz hb. J Nucl Med. 2004 Oct;45(10):1725-33. J Nucl Med. 2004. PMID: 15471841 Free article. Clinical Trial.

10

166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.

Breitz HB, Wendt RE 3rd, Stabin MS, Shen S, Erwin WD, Rajendran JG, Eary JF, Durack L, Delpassand E, Martin W, Meredith RF. Breitz HB, et al. J Nucl Med. 2006 Mar;47(3):534-42. J Nucl Med. 2006. PMID: 16513624 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

39 results

Search Page